Vialwirebiotech, curated
November 21, 2026, 5:36 PM
July 22, 2026
- 5:11 PM · BioWorld5:11 PMGSK’s newly acquired Jideytro wins FDA nod in NSCLC — BioWorld
- 4:48 PM · BioPharma Dive4:48 PMVertex was sole bidder in high-premium Crinetics acquisition — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMUS Senate greenlights bill to tame biologic patent thickets — BioWorld
- 12:00 PM · BioWorld12:00 PMArrowhead rises on phase III hypertriglyceridemia readout — BioWorld
- 12:00 PM · BioWorld12:00 PMDrum KIT: Celldex CSU rhythm still on post-barzo PN phase II — BioWorld
- 10:50 AM · Pharmaceutical Technology10:50 AMSpeciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing — Pharmaceutical Technology
- 10:12 AM · Pharmaceutical Technology10:12 AMSamsung Biologics: geographic diversification is a sound business decision — Pharmaceutical Technology
- 9:00 AM · BioWorld9:00 AMPharmability’s TIR-C gains trial clearance for atopic dermatitis — BioWorld
- 9:00 AM · BioWorld9:00 AMVerismo unveils CLDN6-targeting KIR-CAR program — BioWorld
- 9:00 AM · BioWorld9:00 AMFinancing at Immitra Bio to advance in vivo gene editing therapies — BioWorld
- 9:00 AM · BioWorld9:00 AMEstrigenix Therapeutics raises financing to advance ERβ platform — BioWorld
- 5:50 AM · Bloomberg — Technology5:50 AMRetina Chip Designed to Restore Sight to Go on Sale in Europe — Bloomberg — Technology
- 5:41 AM · Pharmaceutical Technology5:41 AMKyowa Kirin EMEA’s Crysvita approved by EC for infants with XLH — Pharmaceutical Technology
- 4:49 AM · Pharmaceutical Technology4:49 AMCellares and Papillon partner for PPL-001 manufacturing automation — Pharmaceutical Technology
July 21, 2026
- 9:27 PM · TechCrunch
- 8:44 PM · FT — Pharmaceuticals8:44 PMTrump plans 100% tariffs on generic drugs in 2028 — FT — Pharmaceuticals
- 7:00 PM · SCMP — Tech7:00 PMWhat’s at stake as Beijing beats global peers with first approval of novel therapy — SCMP — Tech
- 12:00 PM · BioWorld12:00 PMAgios’ phase II tebapivat splats in SCD, Pyrukynd top of mind — BioWorld
- 12:00 PM · BioWorld12:00 PMUS-based Axiom plans Hong Kong listing — BioWorld
- 11:45 AM · BioPharma Dive11:45 AMNovo sues Lilly, alleging ‘misleading’ advertising of obesity drugs — BioPharma Dive
- 11:00 AM · BioWorld11:00 AMHansoh takes newco route to globalize IL-23 asset — BioWorld
- 11:00 AM · BioWorld11:00 AMAdvancell raises $315M to power global isotope strategy — BioWorld
- 11:00 AM · BioWorld11:00 AMAsia deal flurry draws AZ, Spero to $1B+ Dizal, Innovent assets — BioWorld
- 10:53 AM · BioPharma Dive10:53 AMNovartis climbs on upbeat drug sales as key readouts loom — BioPharma Dive
- 10:15 AM · Nikkei Asia10:15 AMIndia approves its first dengue vaccine, from Japan's Takeda — Nikkei Asia
- 10:10 AM · Pharmaceutical Executive10:10 AM<![CDATA[FDA Grants Emergency Use Authorization for Seegene’s Multiplex PCR Assay ]]> — Pharmaceutical Executive
- 9:37 AM · STAT News
- 9:00 AM · BioWorld9:00 AMAkari and Whitehawk collaborate on ADC research — BioWorld
- 9:00 AM · BioWorld9:00 AMBreezebio and Ligachem partner on cancer vaccine research — BioWorld
- 9:00 AM · Labiotech (EU)9:00 AMRoche’s new gene sequencer on the market: where do current players stand? — Labiotech (EU)
- 8:38 AM · Drug Discovery World8:38 AMNew drug could change post-progression treatment of EGFR-NSCLC — Drug Discovery World
- 6:12 AM · Pharmaceutical Technology6:12 AMBristol Myers, NVIDIA join forces to build life science’s ‘most powerful’ AI factory — Pharmaceutical Technology
- 5:08 AM · Pharmaceutical Technology5:08 AMEMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168 — Pharmaceutical Technology
- 5:04 AM · Drug Discovery World5:04 AMAllogeneic CAR-T achieves durable remissions in metastatic solid tumours — Drug Discovery World
- 4:31 AM · Pharmaceutical Technology4:31 AMHalozyme and Incyte sign licence agreement for INCA033989 formulations — Pharmaceutical Technology
- 4:30 AM · STAT News
- 12:00 AM · FT — Pharmaceuticals12:00 AMInvestors bet on AI drug discovery despite approval gap — FT — Pharmaceuticals
July 20, 2026
- 7:39 PM · TechCrunch